{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:40Z","timestamp":1792783360621,"version":"4.5.0"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Research Foundation","award":["MRF-145-0011-DG-HARV-C0913"],"award-info":[{"award-number":["MRF-145-0011-DG-HARV-C0913"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>The IOF Epidemiology and Quality of Life Working Group has reviewed the potential role of population screening for high hip fracture risk against well-established criteria. The report concludes that such an approach should strongly be considered in many health care systems to reduce the burden of hip fractures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The burden of long-term osteoporosis management falls on primary care in most healthcare systems. However, a wide and stable treatment gap exists in many such settings; most of which appears to be secondary to a lack of awareness of fracture risk. Screening is a public health measure for the purpose of identifying individuals who are likely to benefit from further investigations and\/or treatment to reduce the risk of a disease or its complications. The purpose of this report was to review the evidence for a potential screening programme to identify postmenopausal women at increased risk of hip fracture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The approach took well-established criteria for the development of a screening program, adapted by the UK National Screening Committee, and sought the opinion of 20 members of the International Osteoporosis Foundation\u2019s Working Group on Epidemiology and Quality of Life as to whether each criterion was met (yes, partial or no). For each criterion, the evidence base was then reviewed and summarized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Conclusion<\/jats:title>\n                    <jats:p>The report concludes that evidence supports the proposal that screening for high fracture risk in primary care should strongly be considered for incorporation into many health care systems to reduce the burden of fractures, particularly hip fractures. The key remaining hurdles to overcome are engagement with primary care healthcare professionals, and the implementation of systems that facilitate and maintain the screening program.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-022-01117-6","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T05:02:53Z","timestamp":1656392573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology\/Quality of Life Working Group"],"prefix":"10.1007","volume":"17","author":[{"given":"P.","family":"Chotiyarnwong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. V.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lorentzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Prieto-Alhambra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Abrahamsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Borgstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bruyere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Diaz-Curiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. P.","family":"Dimai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Grigorie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Khashayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Lewiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"Lorenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ortolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Szulc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. A.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"1117_CR1","unstructured":"Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. World Health Organization https:\/\/apps.who.int\/iris\/handle\/10665\/37650. Accessed 18 Aug 2021"},{"key":"1117_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00198-011-1876-7","volume":"23","author":"L Shepstone","year":"2012","unstructured":"Shepstone L, Fordham R, Lenaghan E et al (2012) A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int 23:2507\u20132515","journal-title":"Osteoporos Int"},{"key":"1117_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(17)32640-5","volume":"391","author":"L Shepstone","year":"2018","unstructured":"Shepstone L, Lenaghan E, Cooper C et al (2018) Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 391:741\u2013747","journal-title":"Lancet"},{"key":"1117_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/jbmr.3411","volume":"33","author":"E McCloskey","year":"2018","unstructured":"McCloskey E, Johansson H, Harvey NC et al (2018) Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures-a post hoc analysis of the SCOOP study. J Bone Miner Res 33:1020\u20131026","journal-title":"J Bone Miner Res"},{"key":"1117_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00198-019-05142-z","volume":"31","author":"CM Parsons","year":"2019","unstructured":"Parsons CM, Harvey N, Shepstone L et al (2019) Systematic screening using FRAX((R)) leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporos Int 31:67\u201375","journal-title":"Osteoporos Int"},{"key":"1117_CR6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/jbmr.3381","volume":"33","author":"DA Turner","year":"2018","unstructured":"Turner DA, Khioe RFS, Shepstone L et al (2018) The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP study. J Bone Miner Res 33:845\u2013851","journal-title":"J Bone Miner Res"},{"key":"1117_CR7","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239\u20132256","journal-title":"Osteoporos Int"},{"key":"1117_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","volume":"94","author":"Anon","year":"1993","unstructured":"Anon (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646\u2013650","journal-title":"Am J Med"},{"key":"1117_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jocd.2011.04.010","volume":"14","author":"WD Leslie","year":"2011","unstructured":"Leslie WD, Morin S (2011) Fracture burden in relation to low bone mineral density and FRAX((R)) probability. J Clin Densitom 14:279\u2013285","journal-title":"J Clin Densitom"},{"key":"1117_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11657-014-0187-y","volume":"9","author":"A Svedbom","year":"2014","unstructured":"Svedbom A, Ivergard M, Hernlund E, Rizzoli R, Kanis JA (2014) Epidemiology and economic burden of osteoporosis in Switzerland. Arch Osteoporos 9:187","journal-title":"Arch Osteoporos"},{"key":"1117_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgstrom F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82","journal-title":"Arch Osteoporos"},{"key":"1117_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","volume":"15","author":"F Borgstrom","year":"2020","unstructured":"Borgstrom F, Karlsson L, Ortsater G et al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15:59","journal-title":"Arch Osteoporos"},{"key":"1117_CR13","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733","journal-title":"Osteoporos Int"},{"key":"1117_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00198-011-1601-6","volume":"22","author":"C Cooper","year":"2011","unstructured":"Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA, Epidemiology ICWGoF (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277\u20131288","journal-title":"Osteoporos Int"},{"key":"1117_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/13697137.2021.1951206","volume":"25","author":"M Lorentzon","year":"2022","unstructured":"Lorentzon M, Johansson H, Harvey NC, Liu E, Vandenput L, McCloskey EV, Kanis JA (2022) Osteoporosis and fractures in women: the burden of disease. Climacteric 25:4\u201310","journal-title":"Climacteric"},{"key":"1117_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","volume":"8","author":"A Svedbom","year":"2013","unstructured":"Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8:137","journal-title":"Arch Osteoporos"},{"key":"1117_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136","journal-title":"Arch Osteoporos"},{"key":"1117_CR18","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s00198-015-3154-6","volume":"26","author":"A Oden","year":"2015","unstructured":"Oden A, McCloskey EV, Kanis JA, Harvey NC, Johansson H (2015) Burden of high fracture probability worldwide: secular increases 2010\u20132040. Osteoporos Int 26:2243\u20132248","journal-title":"Osteoporos Int"},{"key":"1117_CR19","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C, Epidemiology IOFWGo, Quality of L, (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239\u20132256","journal-title":"Osteoporos Int"},{"key":"1117_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11914-008-0026-4","volume":"6","author":"SD Berry","year":"2008","unstructured":"Berry SD, Miller RR (2008) Falls: epidemiology, pathophysiology, and relationship to fracture. Curr Osteoporos Rep 6:149\u2013154","journal-title":"Curr Osteoporos Rep"},{"issue":"Suppl 4","key":"1117_CR21","first-page":"1","volume":"34","author":"M Gibson","year":"1987","unstructured":"Gibson M (1987) The prevention of falls in later life. Dan Med Bull 34(Suppl 4):1\u201324","journal-title":"Dan Med Bull"},{"key":"1117_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s001980170112","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417\u2013427","journal-title":"Osteoporos Int"},{"key":"1117_CR23","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1136\/bmj.307.6914.1248","volume":"307","author":"GS Keene","year":"1993","unstructured":"Keene GS, Parker MJ, Pryor GA (1993) Mortality and morbidity after hip fractures. BMJ 307:1248\u20131250","journal-title":"BMJ"},{"key":"1117_CR24","first-page":"260","volume":"319","author":"G Poor","year":"1995","unstructured":"Poor G, Atkinson EJ, O\u2019Fallon WM, Melton LJ 3rd (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop 319:260\u2013265","journal-title":"Clin Orthop"},{"key":"1117_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468\u2013473","journal-title":"Bone"},{"key":"1117_CR26","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","volume":"20","author":"O Johnell","year":"2005","unstructured":"Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185\u20131194","journal-title":"J Bone Miner Res"},{"key":"1117_CR27","volume-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","author":"WHO","year":"1994","unstructured":"WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva"},{"key":"1117_CR28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137\u20131141","journal-title":"J Bone Miner Res"},{"key":"1117_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","volume":"42","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467\u2013475","journal-title":"Bone"},{"key":"1117_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","volume":"154","author":"US Preventive Services Task Force","year":"2011","unstructured":"US Preventive Services Task Force (2011) Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 154:356\u2013364","journal-title":"Ann Intern Med"},{"issue":"24","key":"1117_CR31","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama20187498","volume":"319","author":"US Preventive Services Task Force","year":"2018","unstructured":"US Preventive Services Task Force (2018) Screening for osteoporosis to prevent fractures US preventive services task force recommendation statement. JAMA 319(24):2521\u20132531. https:\/\/doi.org\/10.1001\/jama20187498","journal-title":"JAMA"},{"key":"1117_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2442","volume":"340","author":"GS Collins","year":"2010","unstructured":"Collins GS, Altman DG (2010) An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ 340:c2442","journal-title":"BMJ"},{"key":"1117_CR33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D'Agostino Sr","year":"2008","unstructured":"D\u2019Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743\u2013753","journal-title":"Circulation"},{"key":"1117_CR34","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G et al (2014) 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:2935\u20132959","journal-title":"J Am Coll Cardiol"},{"key":"1117_CR35","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","volume":"16","author":"C De Laet","year":"2005","unstructured":"De Laet C, Kanis JA, Oden A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330\u20131338","journal-title":"Osteoporos Int"},{"key":"1117_CR36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375\u2013382","journal-title":"Bone"},{"key":"1117_CR37","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.bone.2004.06.017","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A et al (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35:1029\u20131037","journal-title":"Bone"},{"key":"1117_CR38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1359\/JBMR.040134","volume":"19","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893\u2013899","journal-title":"J Bone Miner Res"},{"key":"1117_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006983","volume":"96","author":"AL Xue","year":"2017","unstructured":"Xue AL, Wu SY, Jiang L, Feng AM, Guo HF, Zhao P (2017) Bone fracture risk in patients with rheumatoid arthritis: a meta-analysis. Medicine (Baltimore) 96:e6983","journal-title":"Medicine (Baltimore)"},{"key":"1117_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00198-018-4717-0","volume":"30","author":"T Vilaca","year":"2019","unstructured":"Vilaca T, Walsh J, Eastell R (2019) Discordant pattern of peripheral fractures in diabetes: a meta-analysis on the risk of wrist and ankle fractures. Osteoporos Int 30:135\u2013143","journal-title":"Osteoporos Int"},{"key":"1117_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/aje\/kwm106","volume":"166","author":"M Janghorbani","year":"2007","unstructured":"Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495\u2013505","journal-title":"Am J Epidemiol"},{"key":"1117_CR42","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1002\/jbmr.1759","volume":"27","author":"WD Leslie","year":"2012","unstructured":"Leslie WD, Rubin MR, Schwartz AV, Kanis JA (2012) Type 2 diabetes and bone. J Bone Miner Res 27:2231\u20132237","journal-title":"J Bone Miner Res"},{"key":"1117_CR43","unstructured":"Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK, University of Sheffield"},{"key":"1117_CR44","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1001\/jama.288.18.2300","volume":"288","author":"D Feskanich","year":"2002","unstructured":"Feskanich D, Willett W, Colditz G (2002) Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 288:2300\u20132306","journal-title":"JAMA"},{"key":"1117_CR45","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00198-019-05106-3","volume":"30","author":"WD Leslie","year":"2019","unstructured":"Leslie WD, Morin SN, Lix LM, Martineau P, Bryanton M, McCloskey EV, Johansson H, Harvey NC, Kanis JA (2019) Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study. Osteoporos Int 30:2195\u20132203","journal-title":"Osteoporos Int"},{"key":"1117_CR46","first-page":"9","volume":"5","author":"A Morrison","year":"2013","unstructured":"Morrison A, Fan T, Sen SS, Weisenfluh L (2013) Epidemiology of falls and osteoporotic fractures: a systematic review. Clinicoecon Outcomes Res 5:9\u201318","journal-title":"Clinicoecon Outcomes Res"},{"key":"1117_CR47","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johnell O, Oden A et al (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155\u2013162","journal-title":"Osteoporos Int"},{"key":"1117_CR48","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00198-004-1734-y","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737\u2013742","journal-title":"Osteoporos Int"},{"key":"1117_CR49","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* Clinical Practice Guideline. J Clin Endocrinol Metab 104:1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"key":"1117_CR50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43","journal-title":"Arch Osteoporos"},{"key":"1117_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, the Committees of Scientific A, National Societies of the International Osteoporosis F (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","journal-title":"Osteoporos Int"},{"key":"1117_CR52","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1503\/cmaj.100771","volume":"182","author":"A Papaioannou","year":"2010","unstructured":"Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864\u20131873","journal-title":"CMAJ"},{"key":"1117_CR53","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 25:2359\u20132381","journal-title":"Osteoporos Int"},{"key":"1117_CR54","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00198-016-3773-6","volume":"28","author":"NC Harvey","year":"2017","unstructured":"Harvey NC, Biver E, Kaufman JM et al (2017) The role of calcium supplementation in healthy musculoskeletal ageing\u202f: an expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporos Int 28:447\u2013462","journal-title":"Osteoporos Int"},{"key":"1117_CR55","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine S (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911\u20131930","journal-title":"J Clin Endocrinol Metab"},{"key":"1117_CR56","unstructured":"Scientific Advisory Committee on Nutrition (2016) Vitamin D and health https:\/\/www.gov.uk\/government\/groups\/scientific-advisory-committee-on-nutrition. Accessed 18 Aug 2021"},{"key":"1117_CR57","doi-asserted-by":"publisher","first-page":"P23","DOI":"10.1530\/EJE-18-0736","volume":"180","author":"P Lips","year":"2019","unstructured":"Lips P, Cashman KD, Lamberg-Allardt C, Bischoff-Ferrari HA, Obermayer-Pietsch B, Bianchi ML, Stepan J, El-Hajj Fuleihan G, Bouillon R (2019) Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. Eur J Endocrinol 180:P23\u2013P54","journal-title":"Eur J Endocrinol"},{"key":"1117_CR58","unstructured":"Society NO (2013) Vitamin D and bone health: a practical clinical guideline for patient management. https:\/\/www.nos.org.uk\/document.doc?id=1352. Accessed 18 Aug 2021"},{"key":"1117_CR59","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00198-015-3386-5","volume":"27","author":"CM Weaver","year":"2016","unstructured":"Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS, Liu S, Looker AC, Wallace TC, Wang DD (2016) Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int 27:367\u2013376","journal-title":"Osteoporos Int"},{"key":"1117_CR60","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1007\/s00198-016-3699-z","volume":"27","author":"CM Weaver","year":"2016","unstructured":"Weaver CM, Dawson-Hughes B, Lappe JM, Wallace TC (2016) Erratum and additional analyses re: Calcium plus vitamin D supplementation and the risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int 27:2643\u20132646","journal-title":"Osteoporos Int"},{"key":"1117_CR61","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1001\/jama.2017.19344","volume":"318","author":"JG Zhao","year":"2017","unstructured":"Zhao JG, Zeng XT, Wang J, Liu L (2017) Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis. JAMA 318:2466\u20132482","journal-title":"JAMA"},{"key":"1117_CR62","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385\u2013397","journal-title":"Osteoporos Int"},{"key":"1117_CR63","unstructured":"Kanis J.A. on behalf of the WHO Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK, Sheffield"},{"key":"1117_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3427","volume":"344","author":"J Hippisley-Cox","year":"2012","unstructured":"Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344:e3427","journal-title":"BMJ"},{"key":"1117_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4229","volume":"339","author":"J Hippisley-Cox","year":"2009","unstructured":"Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339:b4229","journal-title":"BMJ"},{"key":"1117_CR66","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1210\/jc.2006-1476","volume":"92","author":"ND Nguyen","year":"2007","unstructured":"Nguyen ND, Eisman JA, Center JR, Nguyen TV (2007) Risk factors for fracture in nonosteoporotic men and women. J Clin Endocrinol Metab 92:955\u2013962","journal-title":"J Clin Endocrinol Metab"},{"key":"1117_CR67","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","volume":"11","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV, Advisory Board of the National Osteoporosis Guideline G (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25","journal-title":"Arch Osteoporos"},{"key":"1117_CR68","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00198-011-1864-y","volume":"23","author":"H Johansson","year":"2012","unstructured":"Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23:907\u2013915","journal-title":"Osteoporos Int"},{"key":"1117_CR69","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s00198-015-3176-0","volume":"26","author":"E McCloskey","year":"2015","unstructured":"McCloskey E, Kanis JA, Johansson H et al (2015) FRAX-based assessment and intervention thresholds\u2013an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 26:2091\u20132099","journal-title":"Osteoporos Int"},{"key":"1117_CR70","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11657-018-0510-0","volume":"13","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Harvey NC, McCloskey EV (2018) A brief history of FRAX. Arch Osteoporos 13:118","journal-title":"Arch Osteoporos"},{"key":"1117_CR71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40520-019-01432-y","volume":"32","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, Johansson H, Liu E, Vandenput L, Lorentzon M, Leslie WD, McCloskey EV (2020) A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res 32:187\u2013196","journal-title":"Aging Clin Exp Res"},{"key":"1117_CR72","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229\u2013238","journal-title":"Osteoporos Int"},{"key":"1117_CR73","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00198-020-05435-8","volume":"31","author":"MA Clynes","year":"2020","unstructured":"Clynes MA, Westbury LD, Dennison EM et al (2020) Bone densitometry worldwide: a global survey by the ISCD and IOF. Osteoporos Int 31:1779\u20131786","journal-title":"Osteoporos Int"},{"key":"1117_CR74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11914-020-00566-7","volume":"18","author":"EM Curtis","year":"2020","unstructured":"Curtis EM, Woolford S, Holmes C, Cooper C, Harvey NC (2020) General and specific considerations as to why osteoporosis-related care is often suboptimal. Curr Osteoporos Rep 18:38\u201346","journal-title":"Curr Osteoporos Rep"},{"key":"1117_CR75","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00198-016-3894-y","volume":"28","author":"NC Harvey","year":"2017","unstructured":"Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28:1507\u20131529","journal-title":"Osteoporos Int"},{"key":"1117_CR76","unstructured":"National Institute for Health and Care Excellence (2012) NICE Clinical Guideline 146. Osteoporosis: assessing the risk of fragility fracture. https:\/\/www.nice.org.uk\/guidance\/cg146. Accessed 19 May 2022"},{"key":"1117_CR77","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","volume":"18","author":"JA Kanis","year":"2007","unstructured":"Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033\u20131046","journal-title":"Osteoporos Int"},{"key":"1117_CR78","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/jnci\/djm224","volume":"99","author":"RT Chlebowski","year":"2007","unstructured":"Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA, Women\u2019s Health Initiative I (2007) Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 99:1695\u20131705","journal-title":"J Natl Cancer Inst"},{"key":"1117_CR79","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2018.6537","volume":"319","author":"M Viswanathan","year":"2018","unstructured":"Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, Kahwati LC (2018) Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 319:2532\u20132551","journal-title":"JAMA"},{"key":"1117_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-013-2409-3","volume":"25","author":"WD Leslie","year":"2014","unstructured":"Leslie WD, Lix LM (2014) Comparison between various fracture risk assessment tools. Osteoporos Int 25:1\u201321","journal-title":"Osteoporos Int"},{"key":"1117_CR81","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-207907","volume":"74","author":"A Marques","year":"2015","unstructured":"Marques A, Ferreira RJ, Santos E, Loza E, Carmona L, da Silva JA (2015) The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis 74:1958\u20131967","journal-title":"Ann Rheum Dis"},{"key":"1117_CR82","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00198-015-3025-1","volume":"26","author":"S Nayak","year":"2015","unstructured":"Nayak S, Edwards DL, Saleh AA, Greenspan SL (2015) Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density. Osteoporos Int 26:1543\u20131554","journal-title":"Osteoporos Int"},{"key":"1117_CR83","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00198-011-1846-0","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423\u2013431","journal-title":"Osteoporos Int"},{"key":"1117_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6755","volume":"356","author":"N Dagan","year":"2017","unstructured":"Dagan N, Cohen-Stavi C, Leventer-Roberts M, Balicer RD (2017) External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study. BMJ 356:i6755","journal-title":"BMJ"},{"key":"1117_CR85","doi-asserted-by":"crossref","unstructured":"Baleanu F, Iconaru L, Charles A, et al. (2021) Independent external validation of FRAX and Garvan fracture risk calculators: a sub-study of the FRISBEE cohort. Journal of Bone and Mineral Research (eprint ahead of publication) 101002\/jbm410532","DOI":"10.1016\/j.bonr.2021.100976"},{"key":"1117_CR86","unstructured":"National Institute for Clinical Excellence (2017) Bisphosphonates for treating osteoporosis. https:\/\/www.niceorguk\/guidance\/ta464\/resources\/bisphosphonates-for-treating-osteoporosis-pdf-82604905556677. Accessed 18 Aug 2021"},{"key":"1117_CR87","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(17)32850-7","volume":"390","author":"NC Harvey","year":"2017","unstructured":"Harvey NC, McCloskey E, Kanis JA, Compston J, Cooper C (2017) Bisphosphonates in osteoporosis: NICE and easy? Lancet 390:2243\u20132244","journal-title":"Lancet"},{"key":"1117_CR88","unstructured":"NICE. (2017) Osteoporosis. NICE Quality Standard 149. NICE, 2017. Available at: www.nice.org.uk\/qs149. Accessed 18 Aug 2021"},{"key":"1117_CR89","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.maturitas.2013.05.013","volume":"75","author":"J Compston","year":"2013","unstructured":"Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75:392\u2013396","journal-title":"Maturitas"},{"key":"1117_CR90","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.maturitas.2008.11.022","volume":"62","author":"J Compston","year":"2009","unstructured":"Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105\u2013108","journal-title":"Maturitas"},{"key":"1117_CR91","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"S Lekamwasam","year":"2012","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257\u20132276","journal-title":"Osteoporos Int"},{"key":"1117_CR92","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00198-017-4341-4","volume":"29","author":"P Clark","year":"2018","unstructured":"Clark P, Denova-Gutierrez E, Zerbini C et al (2018) FRAX-based intervention and assessment thresholds in seven Latin American countries. Osteoporos Int 29:707\u2013715","journal-title":"Osteoporos Int"},{"key":"1117_CR93","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11657-021-00962-1","volume":"16","author":"O Lesnyak","year":"2021","unstructured":"Lesnyak O, Zakroyeva A, Babalyan V et al (2021) FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan. Arch Osteoporos 16:87","journal-title":"Arch Osteoporos"},{"key":"1117_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11070","volume":"11","author":"JA Kanis","year":"2007","unstructured":"Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1\u2013256","journal-title":"Health Technol Assess"},{"key":"1117_CR95","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","volume":"17","author":"M Sekhon","year":"2017","unstructured":"Sekhon M, Cartwright M, Francis JJ (2017) Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res 17:88","journal-title":"BMC Health Serv Res"},{"key":"1117_CR96","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00330-010-1845-0","volume":"20","author":"J Damilakis","year":"2010","unstructured":"Damilakis J, Adams JE, Guglielmi G, Link TM (2010) Radiation exposure in X-ray-based imaging techniques used in osteoporosis. Eur Radiol 20:2707\u20132714","journal-title":"Eur Radiol"},{"key":"1117_CR97","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00198-016-3696-2","volume":"28","author":"EV McCloskey","year":"2017","unstructured":"McCloskey EV, Johansson H, Harvey NC, Compston J, Kanis JA (2017) Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK-an analysis of anonymous website activity. Osteoporos Int 28:71\u201376","journal-title":"Osteoporos Int"},{"key":"1117_CR98","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11657-019-0613-2","volume":"14","author":"P Chotiyarnwong","year":"2019","unstructured":"Chotiyarnwong P, Harvey NC, Johansson H, Liu E, Lorentzen M, Kanis JA, McCloskey EV (2019) Temporal changes in access to FRAX(R) in Thailand between 2010 and 2018. Arch Osteoporos 14:66","journal-title":"Arch Osteoporos"},{"key":"1117_CR99","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/fampra\/cmr069","volume":"29","author":"CL Emmett","year":"2012","unstructured":"Emmett CL, Redmond NM, Peters TJ, Clarke S, Shepstone L, Lenaghan E, Shaw AR (2012) Acceptability of screening to prevent osteoporotic fractures: a qualitative study with older women. Fam Pract 29:235\u2013242","journal-title":"Fam Pract"},{"key":"1117_CR100","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11657-013-0144-1","volume":"8","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L, Lems WF, McCloskey EV, Rizzoli R, Stenmark J (2013) SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 8:144","journal-title":"Arch Osteoporos"},{"key":"1117_CR101","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.afos.2019.09.005","volume":"5","author":"R Coronado-Zarco","year":"2019","unstructured":"Coronado-Zarco R, Olascoaga-Gomez de Leon A, Garcia-Lara A, Quinzanos-Fresnedo J, Nava-Bringas TI, Macias-Hernandez SI (2019) Nonpharmacological interventions for osteoporosis treatment: systematic review of clinical practice guidelines. Osteoporos Sarcopenia 5:69\u201377","journal-title":"Osteoporos Sarcopenia"},{"key":"1117_CR102","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40520-021-01970-4","volume":"34","author":"R Rizzoli","year":"2022","unstructured":"Rizzoli R (2022) Dairy products and bone health. Aging Clin Exp Res 34:9\u201324","journal-title":"Aging Clin Exp Res"},{"key":"1117_CR103","doi-asserted-by":"publisher","first-page":"M107","DOI":"10.1093\/geronj\/44.4.M107","volume":"44","author":"SR Cummings","year":"1989","unstructured":"Cummings SR, Nevitt MC (1989) A hypothesis: the causes of hip fractures. J Gerontol 44:M107-111","journal-title":"J Gerontol"},{"key":"1117_CR104","doi-asserted-by":"publisher","unstructured":"Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE (2012) Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev\u00a0\u00a02012(9):CD007146. https:\/\/doi.org\/10.1002\/14651858.CD007146.pub3","DOI":"10.1002\/14651858.CD007146.pub3"},{"key":"1117_CR105","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2002183","volume":"383","author":"S Bhasin","year":"2020","unstructured":"Bhasin S, Gill TM, Reuben DB et al (2020) A randomized trial of a multifactorial strategy to prevent serious fall injuries. N Engl J Med 383:129\u2013140","journal-title":"N Engl J Med"},{"key":"1117_CR106","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1056\/NEJMoa2001500","volume":"383","author":"SE Lamb","year":"2020","unstructured":"Lamb SE, Bruce J, Hossain A et al (2020) Screening and intervention to prevent falls and fractures in older people. N Engl J Med 383:1848\u20131859","journal-title":"N Engl J Med"},{"key":"1117_CR107","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1001\/jama.2017.21962","volume":"319","author":"JM Guirguis-Blake","year":"2018","unstructured":"Guirguis-Blake JM, Michael YL, Perdue LA, Coppola EL, Beil TL (2018) Interventions to prevent falls in older adults: updated evidence report and systematic review for the US preventive services task force. JAMA 319:1705\u20131716","journal-title":"JAMA"},{"key":"1117_CR108","doi-asserted-by":"publisher","first-page":"711","DOI":"10.7326\/M14-0317","volume":"161","author":"CJ Crandall","year":"2014","unstructured":"Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161:711\u2013723","journal-title":"Ann Intern Med"},{"key":"1117_CR109","first-page":"1535","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348:1535\u20131541","journal-title":"Fracture Intervention Trial Research Group Lancet"},{"key":"1117_CR110","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"1117_CR111","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1117_CR112","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230\u2013240","journal-title":"Lancet"},{"key":"1117_CR113","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"1117_CR114","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40520-020-01708-8","volume":"33","author":"MR McClung","year":"2021","unstructured":"McClung MR (2021) Role of bone-forming agents in the management of osteoporosis. Aging Clin Exp Res 33:775\u2013791","journal-title":"Aging Clin Exp Res"},{"key":"1117_CR115","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32:198\u2013202","journal-title":"J Bone Miner Res"},{"key":"1117_CR116","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00198-017-4009-0","volume":"28","author":"JA Kanis","year":"2017","unstructured":"Kanis JA, Cooper C, Rizzoli R et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28:2023\u20132034","journal-title":"Osteoporos Int"},{"key":"1117_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1\u201312","journal-title":"Osteoporos Int"},{"key":"1117_CR118","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s001980170102","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12:356\u2013361","journal-title":"Osteoporos Int"},{"key":"1117_CR119","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial. JAMA 288:321\u2013333","journal-title":"JAMA"},{"key":"1117_CR120","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"GL Anderson","year":"2004","unstructured":"Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. JAMA 291:1701\u20131712","journal-title":"JAMA"},{"key":"1117_CR121","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","volume":"290","author":"JA Cauley","year":"2003","unstructured":"Cauley JA, Robbins J, Chen Z et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial. JAMA 290:1729\u20131738","journal-title":"JAMA"},{"key":"1117_CR122","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1359\/jbmr.061008","volume":"22","author":"EV McCloskey","year":"2007","unstructured":"McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22:135\u2013141","journal-title":"J Bone Miner Res"},{"key":"1117_CR123","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","volume":"20","author":"EV McCloskey","year":"2009","unstructured":"McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy\u2013additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811\u2013817","journal-title":"Osteoporos Int"},{"key":"1117_CR124","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00198-015-3406-5","volume":"27","author":"E McCloskey","year":"2016","unstructured":"McCloskey E (2016) A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base. Osteoporos Int 27:417\u2013419","journal-title":"Osteoporos Int"},{"key":"1117_CR125","unstructured":"National Institute for Clinical Excellence NICE (2005) Technology appraisal guidance 87. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Clinical Excellence, London"},{"key":"1117_CR126","unstructured":"NICE (2008) TA161 (revised) Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence. https:\/\/www.nice.org.uk\/guidance\/ta161. Accessed 14 August 2021"},{"key":"1117_CR127","unstructured":"NICE (2008) TA160. Raloxifene for the primary\nprevention of osteoporotic\nfragility fractures in\npostmenopausal women. https:\/\/www.nice.org.uk\/guidance\/ta160. Accessed 19 May 2022"},{"key":"1117_CR128","unstructured":"NICE (2008) TA161 Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. https:\/\/www.nice.org.uk\/guidance\/ta161. Accessed 14 August 2021"},{"key":"1117_CR129","unstructured":"NICE (2010) Denosumab for the prevention of osteoporotic fractures in postmenopausal women. https:\/\/www.nice.org.uk\/guidance\/ta204. Accessed 19 May 2022"},{"key":"1117_CR130","unstructured":"National Institute for Health and Care Excellence (2017) Bisphosphonates for treating osteoporosis. https:\/\/www.nice.org.uk\/guidance\/ta464\/resources\/bisphosphonates-for-treating-osteoporosis-pdf-82604905556677. Updated: Jul 8, 2019. Accessed 18 Aug 2021"},{"key":"1117_CR131","unstructured":"British Orthopaedic Association (2007) The care of patients with fragility fracture. Available at: http:\/\/www.boaacuk\/Publications\/Documents\/The%20Care%20of%20Patients%20with%20Fragility%20Fracturepdf. Accessed 18 Aug 2021"},{"key":"1117_CR132","unstructured":"NICE (2011) Hip fracture: management. Clinical guideline CG124. Published: 22 June 2011 (Updated May 2017) www.nice.org.uk\/guidance\/cg124. Accessed 18 Aug 2021"},{"key":"1117_CR133","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/MLR.0000000000000383","volume":"53","author":"J Neuburger","year":"2015","unstructured":"Neuburger J, Currie C, Wakeman R, Tsang C, Plant F, De Stavola B, Cromwell DA, van der Meulen J (2015) The impact of a national clinician-led audit initiative on care and mortality after hip fracture in England: an external evaluation using time trends in non-audit data. Med Care 53:686\u2013691","journal-title":"Med Care"},{"key":"1117_CR134","doi-asserted-by":"publisher","DOI":"10.1097\/OI9.0000000000000050","volume":"3","author":"TJS Chesser","year":"2020","unstructured":"Chesser TJS, Inman D, Johansen A et al (2020) Hip fracture systems-European experience. OTA Int 3:e050","journal-title":"OTA Int"},{"key":"1117_CR135","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00198-011-1642-x","volume":"22","author":"D Marsh","year":"2011","unstructured":"Marsh D, Akesson K, Beaton DE et al (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051\u20132065","journal-title":"Osteoporos Int"},{"key":"1117_CR136","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s00198-013-2348-z","volume":"24","author":"K Akesson","year":"2013","unstructured":"Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C, Group IOFFW (2013) Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24:2135\u20132152","journal-title":"Osteoporos Int"},{"key":"1117_CR137","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/jbmr.3557","volume":"33","author":"SR Majumdar","year":"2018","unstructured":"Majumdar SR, McAlister FA, Johnson JA et al (2018) Comparing strategies targeting osteoporosis to prevent fractures after an upper extremity fracture (C-STOP Trial): a randomized controlled trial. J Bone Miner Res 33:2114\u20132121","journal-title":"J Bone Miner Res"},{"key":"1117_CR138","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1503\/cmaj.070981","volume":"178","author":"SR Majumdar","year":"2008","unstructured":"Majumdar SR, Johnson JA, McAlister FA, Bellerose D, Russell AS, Hanley DA, Morrish DW, Maksymowych WP, Rowe BH (2008) Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial. CMAJ 178:569\u2013575","journal-title":"CMAJ"},{"key":"1117_CR139","doi-asserted-by":"publisher","first-page":"366","DOI":"10.7326\/0003-4819-141-5-200409070-00011","volume":"141","author":"SR Majumdar","year":"2004","unstructured":"Majumdar SR, Rowe BH, Folk D et al (2004) A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med 141:366\u2013373","journal-title":"Ann Intern Med"},{"key":"1117_CR140","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s40520-021-01844-9","volume":"33","author":"MK Javaid","year":"2021","unstructured":"Javaid MK (2021) Efficacy and efficiency of fracture liaison services to reduce the risk of recurrent osteoporotic fractures. Aging Clin Exp Res 33:2061\u20132067","journal-title":"Aging Clin Exp Res"},{"key":"1117_CR141","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/jbmr.3990","volume":"35","author":"KF Axelsson","year":"2020","unstructured":"Axelsson KF, Johansson H, Lundh D, Moller M, Lorentzon M (2020) Association between recurrent fracture risk and implementation of fracture liaison services in four swedish hospitals: a cohort study. J Bone Miner Res 35:1216\u20131223","journal-title":"J Bone Miner Res"},{"key":"1117_CR142","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-020-05557-z","volume":"32","author":"E McCloskey","year":"2021","unstructured":"McCloskey E, Rathi J, Heijmans S et al (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int 32:251\u2013259","journal-title":"Osteoporos Int"},{"key":"1117_CR143","doi-asserted-by":"publisher","unstructured":"Leroy S, Saunders-Hastings P, Eusebi P, Taieb V, Abrahamsen B, McCloskey EV, Fujiwara S, Libanati C, Moayyeri A (2022) Treatment gap among patients with primary osteoporosis: a systematic literature review and meta-analysis. Osteoporosis International 32 (Suppl 1) (https:\/\/doi.org\/10.1007\/s00198-021-06125-9):S189","DOI":"10.1007\/s00198-021-06125-9):S189"},{"key":"1117_CR144","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1007\/s40520-021-01971-3","volume":"33","author":"ME Bussell","year":"2021","unstructured":"Bussell ME (2021) Improving bone health: addressing the burden through an integrated approach. Aging Clin Exp Res 33:2777\u20132786","journal-title":"Aging Clin Exp Res"},{"key":"1117_CR145","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00198-017-4326-3","volume":"29","author":"KH Rubin","year":"2018","unstructured":"Rubin KH, Rothmann MJ, Holmberg T et al (2018) Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 29:567\u2013578","journal-title":"Osteoporos Int"},{"key":"1117_CR146","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/jbmr.3815","volume":"34","author":"T Merlijn","year":"2019","unstructured":"Merlijn T, Swart KM, van Schoor NM et al (2019) The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. J Bone Miner Res 34:1993\u20132000","journal-title":"J Bone Miner Res"},{"key":"1117_CR147","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00223-014-9950-8","volume":"96","author":"KH Rubin","year":"2015","unstructured":"Rubin KH, Holmberg T, Rothmann MJ et al (2015) The risk-stratified osteoporosis strategy evaluation study (ROSE): a randomized prospective population-based study. Design and baseline characteristics. Calcif Tissue Int 96:167\u2013179","journal-title":"Calcif Tissue Int"},{"key":"1117_CR148","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00198-020-05417-w","volume":"31","author":"T Merlijn","year":"2020","unstructured":"Merlijn T, Swart KMA, Netelenbos JC, Elders PJM (2020) Reply to \u201cScreening for high fracture risk.\u201d Osteoporos Int 31:1183\u20131184","journal-title":"Osteoporos Int"},{"key":"1117_CR149","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-019-05226-w","volume":"31","author":"T Merlijn","year":"2020","unstructured":"Merlijn T, Swart KMA, van der Horst HE, Netelenbos JC, Elders PJM (2020) Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int 31:251\u2013257","journal-title":"Osteoporos Int"},{"key":"1117_CR150","unstructured":"McCloskey EV, Lenaghan E, Clarke S, et al. (2016) Screening based on FRAX fracture risk assessment reduces the incidence of hip fractures in older community-dwelling women \u2013 results from the SCOOP study in the UK Journal of Bone and Mineral Research 31(S1):S40. https:\/\/www.asbmronlinelibrarywileycom\/doi\/epdf\/101002\/jbmr3107. Accessed 18 Aug 2021"},{"key":"1117_CR151","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00198-020-05542-6","volume":"32","author":"EV McCloskey","year":"2021","unstructured":"McCloskey EV, Harvey NC, Johansson H, Lorentzon M, Vandenput L, Liu E, Kanis JA (2021) Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures. Osteoporos Int 32:39\u201346","journal-title":"Osteoporos Int"},{"key":"1117_CR152","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0969-8043(98)00026-8","volume":"50","author":"CF Njeh","year":"1999","unstructured":"Njeh CF, Fuerst T, Hans D, Blake GM, Genant HK (1999) Radiation exposure in bone mineral density assessment. Appl Radiat Isot 50:215\u2013236","journal-title":"Appl Radiat Isot"},{"key":"1117_CR153","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1001\/archinte.1997.00440390121015","volume":"157","author":"DJ Torgerson","year":"1997","unstructured":"Torgerson DJ, Thomas RE, Campbell MK, Reid DM (1997) Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality-of-life results. Arch Intern Med 157:2121\u20132125","journal-title":"Arch Intern Med"},{"key":"1117_CR154","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/j.socscimed.2005.11.009","volume":"62","author":"SD Reventlow","year":"2006","unstructured":"Reventlow SD, Hvas L, Malterud K (2006) Making the invisible body visible. Bone scans, osteoporosis and women\u2019s bodily experiences. Soc Sci Med 62:2720\u20132731","journal-title":"Soc Sci Med"},{"key":"1117_CR155","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1046\/j.1369-6513.2002.00173.x","volume":"5","author":"JC Richardson","year":"2002","unstructured":"Richardson JC, Hassell AB, Hay EM, Thomas E (2002) \u201cI\u2019d rather go and know\u201d: women\u2019s understanding and experience of DEXA scanning for osteoporosis. Health Expect 5:114\u2013126","journal-title":"Health Expect"},{"key":"1117_CR156","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, Dell RM, Adams AL (2020) Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 383:743\u2013753","journal-title":"N Engl J Med"},{"key":"1117_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1\u201323","journal-title":"J Bone Miner Res"},{"key":"1117_CR158","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479\u20131491","journal-title":"J Bone Miner Res"},{"key":"1117_CR159","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1210\/clinem\/dgz295","volume":"105","author":"DM van de Laarschot","year":"2020","unstructured":"van de Laarschot DM, McKenna MJ, Abrahamsen B, Langdahl B, Cohen-Solal M, Guanabens N, Eastell R, Ralston SH, Zillikens MC (2020) Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society. J Clin Endocrinol Metab 105:682\u20131689","journal-title":"J Clin Endocrinol Metab"},{"key":"1117_CR160","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3365","volume":"353","author":"B Abrahamsen","year":"2016","unstructured":"Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R (2016) Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ 353:i3365","journal-title":"BMJ"},{"key":"1117_CR161","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00198-009-1007-x","volume":"21","author":"RJ Barr","year":"2010","unstructured":"Barr RJ, Stewart A, Torgerson DJ, Reid DM (2010) Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk. Osteoporos Int 21:561\u2013568","journal-title":"Osteoporos Int"},{"key":"1117_CR162","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00198-020-05372-6","volume":"31","author":"E Soreskog","year":"2020","unstructured":"Soreskog E, Borgstrom F, Shepstone L et al (2020) Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. Osteoporos Int 31:1499\u20131506","journal-title":"Osteoporos Int"},{"key":"1117_CR163","doi-asserted-by":"crossref","unstructured":"Owen L, Pennington B, Fischer A, Jeong K (2017) The cost-effectiveness of public health interventions examined by NICE from 2011 to 2016. Journal of Public Health | Vol 40, No 3, pp 557\u2013566 | 101093\/pubmed\/fdx119 40:557\u2013566 (510.1093\/pubmed\/fdx1119)","DOI":"10.1093\/pubmed\/fdx119"},{"key":"1117_CR164","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2618","volume":"346","author":"PD Pharoah","year":"2013","unstructured":"Pharoah PD, Sewell B, Fitzsimmons D, Bennett HS, Pashayan N (2013) Cost effectiveness of the NHS breast screening programme: life table model. BMJ 346:f2618","journal-title":"BMJ"},{"issue":"13","key":"1117_CR165","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/11535650-000000000-00000","volume":"8","author":"D Lee","year":"2010","unstructured":"Lee D, Muston D, Sweet A, Cunningham C, Slater A, Lock K (2010) Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60\u201369 years. Appl Health Econ Health Policy 8(13):141\u2013154","journal-title":"Appl Health Econ Health Policy"},{"key":"1117_CR166","unstructured":"Department of Health (2009) Falls and fractures: effective interventions in health and social care. https:\/\/www.laterlifetraining.co.uk\/wp-content\/uploads\/2011\/12\/FF_Effective-Interventions-in-health-and-social-care.pdf. Accessed 19 May 2022"},{"key":"1117_CR167","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00198-019-05270-6","volume":"31","author":"CI Condurache","year":"2020","unstructured":"Condurache CI, Chiu S, Chotiyarnwong P et al (2020) Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study. Osteoporos Int 31:457\u2013464","journal-title":"Osteoporos Int"},{"key":"1117_CR168","unstructured":"Solutions for Public Health (2019) Screening for osteoporosis in postmenopausal women. External review against programme appraisal criteria for the UK National Screening Committee. https:\/\/view-health-screening-recommendations.service.gov.uk\/osteoporosis\/. Accessed 18 Aug 2021"},{"key":"1117_CR169","unstructured":"UK National Screening Committee (2019) Screening for Osteoporosis in Postmenopausal Women 08 November 2019. https:\/\/view-health-screening-recommendations.service.gov.uk\/osteoporosis\/. Accessed 18 Aug 2021"},{"key":"1117_CR170","unstructured":"EUnetHTA OTCA19 Assessment Team. (2019) Screening for osteoporosis in the general population. Collaborative Assessment. Diemen (The Netherlands): EUnetHTA; 2019. Report No.: OTCA19. Available from https:\/\/www.eunethta.eu. Accessed 18 Aug 2021"},{"key":"1117_CR171","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/jnci\/djy013","volume":"110","author":"MH Gail","year":"2018","unstructured":"Gail MH, Pfeiffer RM (2018) Breast cancer risk model requirements for counseling, prevention, and screening. J Natl Cancer Inst 110:994\u20131002","journal-title":"J Natl Cancer Inst"},{"key":"1117_CR172","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/jbmr.1478","volume":"27","author":"EM Clark","year":"2012","unstructured":"Clark EM, Gould V, Morrison L, Ades AE, Dieppe P, Tobias JH (2012) Randomized controlled trial of a primary care-based screening program to identify older women with prevalent osteoporotic vertebral fractures: Cohort for Skeletal Health in Bristol and Avon (COSHIBA). J Bone Miner Res 27:664\u2013671","journal-title":"J Bone Miner Res"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-022-01117-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-022-01117-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-022-01117-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T10:25:42Z","timestamp":1678962342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-022-01117-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":172,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1117"],"URL":"https:\/\/doi.org\/10.1007\/s11657-022-01117-6","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"29 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This narrative article contains no original data and thus issues of ethics, informed consent and patient confidentiality do not apply.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"E.V.M reports consultant\/advisor fees, speaker honoraria and or, research funding from AgNovos, Amgen, Consilient Healthcare, Fresenius Kabi, Gedeon Richter, Internis, Lilly, Novartis, ObsEva, Synexus and UCB, all outside the submitted work. E.M.C. reports lecture fees and travel support from Eli Lilly, Pfizer and UCB, outside the submitted work. N.C.H. reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare and Internis Pharma, outside the submitted work. J.A.K. reports a grant from UCB, outside the submitted work. He is the architect of FRAX\u00ae but has no financial interest. C.C. reports personal fees from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work. B.A. reports grants and personal fees from UCB, personal fees from Amgen, grants from Novartis, grants and personal fees from Pharma-cosmos, grants and personal fees from Kyowa Kirin, personal fees for Gedeon Richter outside the submitted work. BA also serves on the NovoNordisk Foundation Grants Committee on Endocrinology and Metabolism. M.L. reports lecture fees from Amgen, Astellas, Lilly, Meda, Renapharma and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma and Consilient Health, outside the submitted work. D.P-A. reports institutional receipt of speaker fees from AMGEN and UCB Biopharma; consultancy fees from UCB Biopharma; research grants from UCB, Amgen, and Les Laboratoires Servier, all outside of the submitted work. J. A. reports grants and personal fees from Amgen outside the submitted work, grants from Radius and has been an advisor to Gilead and is part of their speaker\u2019s bureau, outside the submitted work. F.B. is employed and is a shareholder in Quantify Research, a health economic research consultancy, outside of the submitted work. O.B. reports grant support from IBSA, MSD, Nutraveris, Novartis, Pfizer, Rottapharm, Servier and Theramex; consulting or lecture fees from Bayer, Genevrier, IBSA, Rottapharm, Servier, SMB and TRB Chemedica; all outside the submitted work. All other authors have no relevant conflicts of interest in relation to the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"87"}}